These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23778008)

  • 1. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
    Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Sakuma M; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
    J Cardiol; 2013 Sep; 62(3):165-70. PubMed ID: 23778008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
    Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Uemura S; Kanauchi M; Doi N; Sakuma M; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
    Circ J; 2012; 76(6):1526-32. PubMed ID: 22447019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
    Saito Y; Morimoto T; Ogawa H; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sugiyama S; Okada S; Akai Y;
    Diabetes Care; 2011 Feb; 34(2):280-5. PubMed ID: 21270185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial.
    Okada S; Morimoto T; Ogawa H; Kanauchi M; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sakuma M; Saito Y;
    Diabetes Care; 2011 Jun; 34(6):1277-83. PubMed ID: 21515838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus.
    Soejima H; Ogawa H; Morimoto T; Okada S; Sakuma M; Nakayama M; Masuda I; Doi N; Uemura S; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
    J Cardiol; 2019 Jan; 73(1):33-37. PubMed ID: 30487058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial.
    Matsumoto C; Ogawa H; Saito Y; Okada S; Soejima H; Sakuma M; Masuda I; Nakayama M; Doi N; Jinnouchi H; Waki M; Morimoto T; ;
    Diabetes Care; 2020 Feb; 43(2):314-320. PubMed ID: 31801787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
    Di Napoli M; Schwaninger M; Cappelli R; Ceccarelli E; Di Gianfilippo G; Donati C; Emsley HC; Forconi S; Hopkins SJ; Masotti L; Muir KW; Paciucci A; Papa F; Roncacci S; Sander D; Sander K; Smith CJ; Stefanini A; Weber D
    Stroke; 2005 Jun; 36(6):1316-29. PubMed ID: 15879341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
    Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
    Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients.
    Soejima H; Ogawa H; Morimoto T; Okada S; Matsumoto C; Nakayama M; Masuda I; Jinnouchi H; Waki M; Saito Y;
    J Cardiol; 2020 Apr; 75(4):387-393. PubMed ID: 31564388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus.
    Yu HI; Sheu WH; Song YM; Liu HC; Lee WJ; Chen YT
    Diabet Med; 2004 Apr; 21(4):336-41. PubMed ID: 15049935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
    Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
    J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile.
    Asegaonkar SB; Marathe A; Tekade ML; Cherekar L; Bavikar J; Bardapurkar J; Ajay R
    J Diabetes Complications; 2011; 25(6):368-70. PubMed ID: 22055258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.
    Linnemann B; Voigt W; Nobel W; Janka HU
    Exp Clin Endocrinol Diabetes; 2006 Mar; 114(3):127-34. PubMed ID: 16636979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.
    Sasso FC; Marfella R; Pagano A; Porta G; Signoriello G; Lascar N; Minutolo R; Carbonara O; Persico M; Piscione F; De Nicola L; Torella R; Paolisso G
    Acta Diabetol; 2015 Apr; 52(2):239-47. PubMed ID: 25109286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of high-density lipoprotein cholesterol levels in elderly diabetic individuals with type IIb dyslipidemia: A 2-year survey of cardiovascular events.
    Ina K; Hayashi T; Araki A; Kawashima S; Sone H; Watanabe H; Ohrui T; Yokote K; Takemoto M; Kubota K; Noda M; Noto H; Ding QF; Zhang J; Yu ZY; Yoon BK; Nomura H; Kuzuya M;
    Geriatr Gerontol Int; 2014 Oct; 14(4):806-10. PubMed ID: 24215618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial.
    Hovens MM; Snoep JD; Groeneveld Y; Frölich M; Tamsma JT; Huisman MV
    Diabetes Obes Metab; 2008 Aug; 10(8):668-74. PubMed ID: 18034847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.